Non-cutaneous melanoma

Summary

Non-cutaneous melanoma (MONDO:0006320) is a cancer and 2 clinical trials. Top therapeutic interventions include ipilimumab and pembrolizumab. A subtype of melanoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	non-cutaneous melanoma
Mondo ID	MONDO:0006320
EFO	EFO:1000397
NCIT	C8711
UMLS	C1334974
MedGen	233761
Is cancer (heuristic)	yes

Also known as: extracutaneous melanoma · non-cutaneous melanoma

Disease family

This is a subtype of melanoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › melanocytic neoplasm › melanoma › non-cutaneous melanoma

Related subtypes (14): scrotum melanoma, amelanotic melanoma, epithelioid cell melanoma, malignant breast melanoma, melanomatosis, cutaneous melanoma, metastatic melanoma, ocular melanoma, spindle cell melanoma, mixed epithelioid and spindle cell melanoma, malignant melanoma of the mucosa, familial melanoma, CDK4 linked melanoma, childhood malignant melanoma

Subtypes (4): mucosal melanoma, vulvar melanoma, primary melanoma of the central nervous system, digestive system melanoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02506153	PHASE3	ACTIVE_NOT_RECRUITING	Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
NCT05628883	PHASE1	COMPLETED	Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IPILIMUMAB	4	1
PEMBROLIZUMAB	4	1